Continence Reports最新文献

{"title":"Parameters which predict detrusor overactivity after adjustable trans obturator male system (ATOMS) implant.","authors":"Miguel Vírseda-Chamorrro ,&nbsp;Sonia Ruiz-Graña ,&nbsp;Jesús Salinas-Casado ,&nbsp;Javier Angulo Cuesta","doi":"10.1016/j.contre.2025.100084","DOIUrl":"10.1016/j.contre.2025.100084","url":null,"abstract":"<div><h3>Aims:</h3><div>To evaluate which parameters predicted the presence of detrusor overactivity after ATOMS implant in patients who had post prostatectomy urinary incontinence (PPI).</div></div><div><h3>Method:</h3><div>We carried out a prospective study in 56 patients submitted to ATOMS implant for PPI. The study consisted of a clinical and urodynamic record before and after ATOMS implantation. We built a multivariate model to find out which variables independently influenced postoperative DO and a ROC curve to decide the best cut-off value.</div></div><div><h3>Results:</h3><div>We found that the preoperative variables were age, detrusor pressure at maximum flow rate (PQmax) the urethral resistance parameter URA and the bladder contractility index (BCI) and the postoperative variables were, the number of ATOMS adjustments, cystometric bladder capacity, bladder compliance, maximum detrusor pressure, PQmax, bladder outflow obstruction index, URA and the presence of acontractile detrusor. The multivariate model showed that the only independent variables were age (inversely related with the presence of postoperative DO), and URA (directly related). The cut-off point of URA was established at 10. 5 cm H2O.</div></div><div><h3>Conclusions:</h3><div>the degree of postoperative resistance measured by the URA parameter and age were the two factors that independently influenced the presence of postoperative DO. It is possible that these parameters are related to the reaction of detrusor muscle to the increase in postoperative urethral resistance.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study","authors":"Max D. Sandler ,&nbsp;Adam D. Williams ,&nbsp;Alan Wein ,&nbsp;Katherine Amin ,&nbsp;Raveen Syan","doi":"10.1016/j.contre.2025.100083","DOIUrl":"10.1016/j.contre.2025.100083","url":null,"abstract":"<div><h3>Purpose:</h3><div>To explore preliminary data on the subjective impact of Glucagon-Like Peptide-1 (GLP-1) agonists, commonly used for diabetes and obesity, on symptoms of overactive bladder (OAB), in order to guide future, larger-scale investigations.</div></div><div><h3>Methods:</h3><div>We distributed an anonymous survey on an online forum. Participants aged 18 or older who had used GLP-1 agonists and experienced OAB symptoms were eligible. We collected data on participants’ OAB symptoms, body weight changes, reasons for GLP-1 prescription, and demographics. Data was analyzed using SAS® software, with significance set at p &lt; 0.05.</div></div><div><h3>Results:</h3><div>Of 33 respondents, 27 identified as female and 6 male. All used semaglutide, primarily for weight loss (96.9%). Four had a urinary condition besides OAB. Eleven (33.3%) reported OAB symptom improvement after starting GLP-1 agonists with mean weight loss of 12.2%, but this was not significantly different from those with no change or worsening symptoms (8.4% and 10% mean weight loss, respectively; p = 0.24). Half of those with OAB episodes at least once daily experienced symptom improvement, compared to 7.7% with less frequent symptoms (p = 0.01). Of participants reporting symptom improvement, 90.91% experienced OAB daily (p = 0.01).</div></div><div><h3>Conclusion:</h3><div>While weight loss can improve OAB symptoms, the impact of GLP-1 agonists remains unclear. Our findings may suggest that those with more frequent OAB symptoms at baseline may derive greater benefit from GLP-1 agonists, offering a potential hypothesis for future investigation. Further studies are needed to explore how these medications impact management of OAB.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100083"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder wall abscess following surgical treatment of complicated diverticulitis: A case report","authors":"Narjes Sweis ,&nbsp;John Smith ,&nbsp;Patrick Bladek ,&nbsp;Steven Garzon ,&nbsp;Omer Acar ,&nbsp;Gerald Gantt","doi":"10.1016/j.contre.2025.100086","DOIUrl":"10.1016/j.contre.2025.100086","url":null,"abstract":"<div><div>Bladder wall abscesses, though rare, pose significant diagnostic challenges due to their nonspecific presentation. This case presents a 47-year-old male with a history of complicated diverticulitis, who developed a bladder wall abscess following treatment for a colocutaneous fistula. Initial imaging showed bladder wall thickening, and the patient later presented with recurrent lower urinary tract symptoms and a fluid collection at the bladder dome. Despite negative urine cultures, antibiotic therapy, and no evidence of a colovesical fistula, the abscess recurred. The patient underwent cystoscopy and transurethral resection of the abscess. This minimally invasive approach was effective, and the patient had a full recovery with no further recurrence. This case emphasizes the need for timely evaluation and a broad differential diagnosis in patients with a history of diverticulitis and persistent bladder symptoms. It also adds valuable insights to the limited knowledge on managing rare bladder wall abscesses.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy of bladder dysfunction — past, present and future","authors":"Karl-Erik Andersson","doi":"10.1016/j.contre.2025.100080","DOIUrl":"10.1016/j.contre.2025.100080","url":null,"abstract":"<div><div>Overactive bladder (OAB) encompasses a variety of conditions that may necessitate different therapeutic strategies. This diversity is evident in the wide range of medications used over the past five decades. Unfortunately, we have too few tools to identify individual conditions and even less information about which condition is best served by which treatment. Many of the drugs have been discontinued primarily due to an unfavorable balance between efficacy and adverse effects. As a result, current treatment guidelines primarily recommend antimuscarinics and <span><math><mi>β</mi></math></span>3-adrenoceptor agonists, with intravesical botulinum toxin injections as a second-line option. While these treatments have documented efficacy, their use is often limited by side effects, adherence challenges, and persistence issues. Personalized treatment approaches may help optimize the use of these medications. However, there is a need for improved therapies, and many promising future therapeutic alternatives can be discussed. However, there seem to be no drugs ready for immediate clinical introduction.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100080"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of the P-funnel, an external urinary collection device, for females in a hospital setting","authors":"Vania Chang (M.S.) ,&nbsp;Joan M. Ching (R.N., D.N.P.) ,&nbsp;Randal P. Ching (Ph.D.)","doi":"10.1016/j.contre.2025.100082","DOIUrl":"10.1016/j.contre.2025.100082","url":null,"abstract":"<div><div><strong>Objectives</strong>: For females with limited mobility, toileting can be challenging, and effective options that foster independence and continence are few. This study examines the usability and effectiveness of the P-funnel^TM, a new external urinary collection device for females with mobility challenges, and postulates its potential for increasing independence, reducing risks for infection and skin breakdown, and sustaining continence.</div><div><strong>Study Design</strong>: Prospective, single-center, survey study of hospitalized female volunteers.</div><div><strong>Methods</strong>: Fourteen hospitalized female patients who met the eligibility criteria were enrolled in this study. Each participant was trained on the use of the P-funnel, performed at least one supine void, then completed a 5-point Likert questionnaire. The survey questions focused on comfort, ease of use, and functionality.</div><div><strong>Results</strong>: The participant’s average satisfaction rating across the 10 question survey was 4.37 out of 5. For overall comfort, 85.8% of the participants scored the P-funnel as 4 or higher (out of 5). For questions concerning ease of use, 92.9% agreed the device was easy to position, and 85.8% agreed it was not difficult to hold the funnel in place while peeing. While 42.9% of the participants did encounter some leakage during use, 90.9% felt the P-funnel was easier to use than what they were currently using and 100% agreed that they would able to use the device confidently and would recommend it to others.</div><div><strong>Conclusions</strong>: Overall the P-funnel functioned well with generally high satisfaction scores for ease of use and comfort. And, for females with ambulatory difficulty, it has the potential to increase independence and reduce the hazards associated with toileting.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sling plication for failed midurethral sling surgery to treat female stress urinary incontinence","authors":"Eva M.P. Remmen,&nbsp;John P.F.A. Heesakkers","doi":"10.1016/j.contre.2025.100081","DOIUrl":"10.1016/j.contre.2025.100081","url":null,"abstract":"<div><h3>Introduction:</h3><div>Stress urinary incontinence (SUI) is a common problem in women. When conservative therapy fails, surgical interventions should be considered. Midurethral slings (MUSs) were introduced in the 1990s and have been the golden standard for surgical treatment of SUI. Despite being the golden standard among several different surgical options for SUI, failure rates vary from 8% to 57%. There is no defined standard of care after failed MUS. Sling plication is a less invasive procedure compared to other surgical options, however data is relatively scarce.</div></div><div><h3>Methods:</h3><div>Three women who underwent sling plication for persistent SUI after retropubic MUS were identified. Sling plication was performed by the same physician. The polypropylene sling was isolated and cut medially. Sling ends were then folded over each other and fixated with prolene sutures. Tensioning of the sling was based on the subjective assessment of the surgeon. Subjective and objective findings were collected before initial placement of MUS, after placement of MUS and at six and twelve weeks after plication of MUS.</div></div><div><h3>Results:</h3><div>All three women had a satisfactory reduction of SUI symptoms after sling plication. Reduction in pad use was clinically relevant, decreasing from two to six large pads to a maximum of two small pads a day. There were no post-operative complications. All women would recommend sling plication to others in the same situation.</div></div><div><h3>Conclusion:</h3><div>Sling plication is an effective, safe and less invasive way of treating persistent or recurrent SUI after midurethral sling surgery and should be considered when counselling patients after failed MUS. Further research with bigger study populations, standardised methods to quantify improvement after plication and longer follow-up is needed to verify our positive results.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary continence outcomes during the transition from laparoscopic to robotic assisted radical prostatectomy: A single surgeon’s Australian regional centre experience","authors":"Basil Razi ,&nbsp;Dane Cole-Clark ,&nbsp;Duncan Self ,&nbsp;Mark Louie-Johnsun","doi":"10.1016/j.contre.2025.100079","DOIUrl":"10.1016/j.contre.2025.100079","url":null,"abstract":"<div><h3>Introduction &amp; Objectives:</h3><div>Robotic assisted laparoscopic radical prostatectomy (RARP) is becoming standard of care for prostate cancer patients requiring surgical intervention. Postoperative continence significantly impacts patients’ quality of life, making functional outcomes a critical focus in the evolution of surgical techniques. Alternative methods, including open and laparoscopic techniques, have been superseded with increased availability of robotic units within Australia. This study aims to review an experienced laparoscopic surgeon’s transition to robotic prostatectomy and the impact on continence.</div></div><div><h3>Methods:</h3><div>Prospective data collection included patient demographics, surgical method, and pad usage at 3 and 12 months postoperatively. The final 100 laparoscopic radical prostatectomy (LRP) cases (May 2019–August 2021) were compared with the first 100 RARP cases (August 2021–February 2023), all performed by the same surgeon. Continence rates were assessed using patient-reported pad usage.</div></div><div><h3>Results:</h3><div>The mean age was similar between LRP (65.3 years) and RARP (65.4 years) groups. Continence rates at 3 and 12 months were 67.0% and 90.4% for LRP patients versus 78% and 94% for RARP patients. Odds ratio analysis indicated LRP patients were 1.75 and 1.66 times more likely to be incontinent at 3 and 12 months, respectively.</div></div><div><h3>Conclusion:</h3><div>RARP demonstrated higher continence rates without evidence of a learning curve during the transition from LRP. These findings underscore the potential for improved patient outcomes with wider adoption of robotic systems in Australia.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"14 ","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transvaginal mechanotherapy for stress urinary incontinence: Principles, cellular and neuromuscular mechanisms of action, and comparison to current gold standard treatments","authors":"Alisha Fulker ,&nbsp;Shravya Kovela ,&nbsp;Marcus Mianulli","doi":"10.1016/j.contre.2024.100077","DOIUrl":"10.1016/j.contre.2024.100077","url":null,"abstract":"<div><div>Mechanotransduction is a scientific principle by which cells sense and respond to mechanical stimuli. Mechanotherapy is the clinical application of mechanotransduction for tissue repair in muscle rehabilitation. Pelvic floor muscle training (PFMT) is currently the conservative gold standard of care for treatment of women with stress urinary incontinence (SUI). Mechanotherapy can increase the effectiveness of PFMT, especially when applied intravaginally for a direct transvaginal treatment to the pelvic floor muscles. With an understanding of the benefits of mechanotherapy, its mechanisms of action, and the resulting neuromuscular recruitment leading to the long-term durability of continence results, transvaginal mechanotherapy has the potential to become a complimentary first-line standard of care for women with SUI.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"13 ","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143103293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravesical migration of intrauterine device: Case report and literature review","authors":"Gamal M. Ghoniem ,&nbsp;Tivoli Nguyen","doi":"10.1016/j.contre.2024.100074","DOIUrl":"10.1016/j.contre.2024.100074","url":null,"abstract":"<div><div>Intrauterine devices are a commonly used method of female contraception that has become increasingly popular worldwide because they are highly effective and convenient to use. However, complications, such as migration to nearby viscera or peritoneal cavity, can occur. The bladder is an especially uncommon destination for migration. Here, we report a rare case of IUD intravesical migration in a 30-year-old female patient presenting with lower abdominal pain and menorrhagia who had an IUD placed 8 years prior.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"12 ","pages":"Article 100074"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of videourodynamics, imaging, and cystoscopy in patients with recurrent urinary tract infections: Should we throw in the kitchen sink?","authors":"G. Chan ,&nbsp;F. Davidovic ,&nbsp;J. Gani","doi":"10.1016/j.contre.2024.100073","DOIUrl":"10.1016/j.contre.2024.100073","url":null,"abstract":"<div><h3>Purpose:</h3><div>Recurrent urinary tract infection (rUTI) remains a common outpatient problem with discordance and paucity of evidence for management. This study aims to evaluate the role of videourodynamics (VUD), additional imaging, and cystoscopy in the complete workup of these patients.</div></div><div><h3>Materials and Methods:</h3><div>A retrospective review was performed on 1421 consecutive patients referred for physician performed VUD. After exclusion criteria, 170 patients were included. Ethics approval was obtained, followed by data collection, and analysis of demographics, symptoms, cystoscopy results, imaging, and VUD parameters. Statistical analyses were performed with IBM SPSS Statistics Version 28. Statistical significance was defined by an alpha level of P <span><math><mrow><mo>≤</mo><mn>0</mn><mo>.</mo><mn>05</mn></mrow></math></span>.</div></div><div><h3>Results:</h3><div>Overall, 117/170 (69%) had identifiable causes of rUTI identified on VUD. There was a statistically significant difference (<em>p</em>&lt;0.001) in identifying a cause in those with voiding symptoms (93/114 <span><math><mo>=</mo></math></span> 82%) compared to those without (24/56 <span><math><mo>=</mo></math></span> 43%). Gender was not predictive of an identifiable cause on VUD (<span><math><mrow><mi>p</mi><mo>=</mo><mn>0</mn><mo>.</mo><mn>47</mn></mrow></math></span>). Neither was a neurogenic history (<span><math><mrow><mi>p</mi><mo>=</mo><mn>0</mn><mo>.</mo><mn>11</mn></mrow></math></span>), diabetes (<span><math><mrow><mi>p</mi><mo>=</mo><mn>0</mn><mo>.</mo><mn>97</mn></mrow></math></span>), or age (<span><math><mrow><mi>p</mi><mo>=</mo><mn>0</mn><mo>.</mo><mn>89</mn></mrow></math></span>). Additional imaging was not diagnostic for rUTI cause. No malignancy was identified on imaging or cystoscopy.</div></div><div><h3>Conclusion:</h3><div>In patients with rUTI, VUD may be an important investigative step to find a possible underlying cause, but it is a scarce resource. As VUD has a higher detection rate in patients with voiding symptoms, by first screening for these patients on history, VUD can be used judiciously. Cystoscopy and additional imaging were not as helpful in identifying a target treatment plan for rUTI, when a VUD had already been done.</div></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"12 ","pages":"Article 100073"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}